Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 3,579 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Spine
Interventions: Immunotherapy, Stereotactic Radiosurgery, Vertebroplasty; Other · Radiation · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Refractory Melanoma
Interventions: DOC1021, Tumor resection, pIFN (peginterferon alfa-2a); Biological · Procedure · Drug
Lead sponsor: Diakonos Oncology Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 8
States / cities: Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 5 more

Conditions: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, Histiocytic Disorders
Interventions: F-choline PET Scan, FDG-PET, biopsy; Radiation · Device · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: PTSD, Trauma
Interventions: Estradiol patch, Placebo patch; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Lateral Epicondylitis (Tennis Elbow)
Interventions: dexamethasone; Drug
Lead sponsor: Travanti Pharma Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
Interventions: Placebo IEM tablet, Abilify MyCite®, D-Tect Patch; Drug · Device
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Garden Grove, California

Conditions: Chronic, Non Malignant Pain
Interventions: EN3270; Drug
Lead sponsor: Durect; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Berlin, New Jersey

Conditions: Lung Cancer
Interventions: Autologous Blood Patch, Standard of Care (per Physician); Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: New Persistent Daily Headache
Interventions: CGRP antibody; Drug
Lead sponsor: Duke University; Other
Eligibility: 10 Years to 18 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Colon Cancer
Interventions: Endocystoscopy During Colonoscopy, Endocytoscope; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Small-cell Lung Cancer
Interventions: Carboplatin, Etoposide, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: Brian Henick, MD; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Degenerative Lesion of Articular Cartilage of Knee
Interventions: ADSC Application, Microfracture; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 3
States / cities: Redwood City, California • Santa Monica, California • Denver, Colorado

Conditions: Atrial Fibrillation, Stroke, Stroke, Cardiovascular, Vascular Cognitive Impairment, Strokes Thrombotic, Stroke, Ischemic
Interventions: Cardiac and Brain MRI; Device
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Esophageal Lesion
Interventions: PillCam ESO Capsule Endoscope; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Eye Movements, Attention, Executive Function
Interventions: Contour Search Task, Stop signal Task, Useful field of View, Attentional capture search task; Other · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Acquired Immunodeficiency Syndrome, Burning Mouth Syndrome, HIV Infection
Interventions: Thalidomide; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoarthritis, Knee
Interventions: AXS-02, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 54
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 49 more

Conditions: Carotid Artery Stenosis
Interventions: Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA); Device
Lead sponsor: Fogarty Clinical Research Inc.; Other
Eligibility: 40 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 2
States / cities: Mountain View, California • Petoskey, Michigan

Conditions: Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions: nicotine lozenge, nicotine patch; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Miami Beach, Florida • Augusta, Georgia + 7 more

Conditions: Molluscum Contagiosum
Interventions: VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102; Combination Product
Lead sponsor: Verrica Pharmaceuticals Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 18
States / cities: Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 15 more

Conditions: Tobacco Use Disorder
Interventions: Nicotine patch; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Piscataway, New Jersey

Conditions: High-Risk Oral Precancerous Disease
Interventions: RP2 Injection; Biological
Lead sponsor: Glenn J. Hanna; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Moderate to Severe Palmoplantar Psoriasis
Interventions: secukinumab 150 mg, secukinumab 300 mg, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Birmingham, Alabama • Phoenix, Arizona • Indianapolis, Indiana + 5 more

Conditions: Nicotine Dependence
Interventions: Standard treatment, Standard treatment+practice quitting, Very low nicotine cigarettes; Behavioral · Drug
Lead sponsor: Rutgers University; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Search by objective public record fields.

Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement

Neuroendocrine Risk for PTSD in Women

Study to Compare the Pharmacokinetics of a Dexamethasone Iontophoretic Patch to a Dexamethasone Injection

A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain

Prolonged Air Leak (PAL) Autologous Blood Patch Intervention Trial

NDPH Biomarker Study in Children and Adolescents

Endocytoscopy and Colorectal Neoplasia

Liver Directed RT + Chemo-immunotherapy for ES-SCLC

Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

Advanced Cardiac Imaging To Predict Embolic Stroke On Brain MRI: A Pilot Study

Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment

An Investigation of Attentional and Inhibitory Processes During Active Visual Search in Humans

Thalidomide to Treat Oral Lesions in HIV-Infected Patients

A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions

Impact of Aspiration Thrombectomy During Carotid Stenting

Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking

Cantharidin Application in Molluscum Patients-1

Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder - 1

Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis

Evaluation of Learning-Theory-Based Smoking Cessation Strategies